Market Chatter: ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial

South Korean biotechnology firm ABL Bio Inc. (KOSDAQ:298380) and its US-based partner I-MAB Biopharma entered a collaboration and supply agreement with New York-based pharmaceutical company Bristol-My

MT NewswiresJun 10 07:36 ET

While Private Equity Firms Own 21% of I-Mab (NASDAQ:IMAB), Retail Investors Are Its Largest Shareholders With 59% Ownership

Yahoo FinanceJun 7 07:46 ET

I-mab has appointed Dr. Phillip Dennis as its Chief Medical Officer.

On June 6th, Gelonghui announced that i-Mab appointed Dr. Phillip Dennis as Chief Medical Officer. Dr. Phillip Dennis will join i-Mab on June 17, 2024, leading global clinical development and serving as a member of i-Mab's executive leadership team. "I am delighted to welcome Dr. Phillip Dennis as our Chief Medical Officer. Dr. Phillip Dennis has extensive experience in oncology drug development.

Gelonghui FinanceJun 6 07:38 ET

Express News | I-Mab Appoints Phillip Dennis, Md, Phd, as Chief Medical Officer

ReutersJun 6 07:00 ET

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of high

I-Mab BiopharmaJun 6 00:00 ET

Bristol Myers Squibb Inks Clinical Trial Pact With I-Mab

Seeking AlphaJun 5 09:15 ET